What is claimed is:

1. A compound which is *trans*-4-[[(5*S*)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2*H*-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1*H*-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid, a hydrate, or a pharmaceutically acceptable salt of said compound.

2. A compound of claim 1 which is *trans*-4-[[(5*S*)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2*H*-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1*H*-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid • hydrate.

3. A compound according to claim 1 or 2 which is *trans*-4-[[(5*S*)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2*H*-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1*H*-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid • hydrate in crystalline form characterized by an X-ray powder diffraction pattern obtained from a CuKα source (λ=1.54056 Å) which comprises peaks at:

a) 7.5, 9.2, 10.7, and 15.5 +/-0.2 in 2θ; or

b) 7.5, 9.2, 10.7, 13.8, 15.0, 15.5, and 19.5 +/-0.2 in 2θ; or

c) 7.5, 9.2, 10.7, 13.8, 11.3, 15.0, 15.5, 17.7, 19.5, and 25.1 +/-0.2 in 2θ.

4. A compound according to any one of claims 1 to 2 which is *trans*-4-[[(5*S*)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2*H*-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1*H*-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid • hydrate in crystalline form characterized by a solid state NMR spectrum which comprises peaks referenced to adamantane (δ = 29.5 ppm) at:

a) 175.6, 168.0, 61.1, 21.2, and 18.3 +/- 0.2 ppm; or

b) 175.6, 168.0, 145.6, 144.8, 61.1, 45.0, 21.2, and 18.3 +/- 0.2 ppm; or

c) 175.6, 168.0, 145.6, 144.8, 139.9, 136.3, 61.1, 53.0, 49.8, 45.0, 21.2, and 18.2 +/- 0.2 ppm.

5. A compound according to claim 1 which is *trans*-4-[[(5*S*)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2*H*-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1*H*-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid, or a pharmaceutically acceptable salt of said compound.

6. A composition comprising *trans*-4-[[(5*S*)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2*H*-tetrazol-5-yl)amino]-2,3,4,5-

tetrahydro-7,9-dimethyl-1*H*-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid, hydrate, or hydrate in crystalline form, according to any one of claims 1 to []5.

7. A composition according to claim 6 comprising *trans*-4-[[(5*S*)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2*H*-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1*H*-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid • hydrate in crystalline form.

8. A composition according to claim 6 comprising greater than ~~about~~ 80 % *trans*-4-[[(5*S*)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2*H*-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1*H*-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid • hydrate in crystalline form.

9 A ~~composition~~ compound according to claim 5 comprising:

trans-4-[[(5*S*)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2*H*-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1*H*-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid, or a pharmaceutically acceptable salt thereof; and

a solvate molecule selected from: water, methanol, ethanol, isopropanol, formic acid, or acetic acid.

10. A ~~composition~~ compound according to claim 9 wherein the *trans*-4-[[(5*S*)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2*H*-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1*H*-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid, or a pharmaceutically acceptable salt thereof, and the solvate molecule is in a molar ratio of between about 1:0.3 to about 1:1 +/- 0.2 (acid or salt:solvate molecule).

11. A compound which is *trans*-4-[[(5*S*)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2*H*-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1*H*-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid • hemi-*tert*-butyl amine salt • hemi ethanol solvate in crystalline form characterized by an X-ray powder diffraction pattern obtained from a CuKα source (λ=1.54056 Å) which comprises peaks at:

a) 5.6, 11.3, 12.6, and 17.9, +/-0.2 in 2θ; or

b) 5.6, 8.0, 11.3, 12.6, 17.9, 20.4, and 24.1, +/-0.2 in 2θ.

15. A compound according to claim 1 wherein the cation for the pharmaceutically acceptable salt is selected from a sodium, potassium, magnesium, calcium, zinc, or *tert*-butyl ammonium.

16. A pharmaceutical composition comprising a compound according to any one of claims 1 to 5 and ~~9~~11-15, and at least one of a pharmaceutically acceptable: carrier, excipient or diluent.


17. A pharmaceutical composition according to claim 16 comprising *trans*-4-[[(5*S*)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2*H*-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1*H*-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid • hydrate.

18. A pharmaceutical composition according to claims 16 and 17 comprising *trans*-4-[[(5*S*)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2*H*-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1*H*-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid • hydrate in crystalline form.

19. Use of a compound according to any one of claims 1 to 5 and ~~10~~9 to 14 for the manufacture of a medicament for the treatment of dyslipidemia.


20. Use of a compound according to any one of claims 1 to 5 and ~~10~~ 9 to 14 for the manufacture of a medicament for the treatment of arthrosclerosis.

21. A method of preparing *trans*-4-[[(5*S*)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2*H*-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1*H*-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid, or a pharmaceutically acceptable salt thereof, said method comprising de-esterifying a compound of formula II:



II;

where R is selected from a C_{1-4} alkyl, C_{1-4} haloalkyl, C_{3-6}cycloalkyl, C_{1-4} alkyl-C_{3-6}cycloalkyl, phenyl, or C_{1-5} alkylphenyl to provide a compound of formula I, or a pharmaceutically acceptable salt thereof



I.